Science News

SASKATOON, Saskatchewan--(BUSINESS WIRE)--ZYUS Life Sciences Corporation (the “Company”) (TSXV: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, is pleased to announce that it has now completed a first tranche (the "First Tranche") of its non-brokered private placement (the "Offering") of up to 1,119,402 units of the Company (each a "Unit") for up to $750,000.00. Under th...

MANHASSET, N.Y.--(BUSINESS WIRE)--To continue its groundbreaking bipolar disorder research, Northwell Health’s The Feinstein Institutes for Medical Research has been awarded $2.3 million and joined the Breakthrough Discoveries for Thriving with Bipolar Disorder (BD²) Integrated Network, a national collaborative research and clinical care initiative aimed at transforming treatment and care for people living with bipolar disorder. Led by Caitlin Millett, PhD, assistant professor in the Feinstein...

JACKSONVILLE, Fla.--(BUSINESS WIRE)--Redwire Corporation (NYSE: RDW) (“Redwire” or the “Company”), a global leader in aerospace and defense technology solutions, today announced that it has commenced an underwritten registered public offering (the “Offering”) of $200,000,000 of its common stock. The Company expects to grant the underwriters a 30-day option to purchase an additional amount of shares of common stock equal to 15% of its common stock sold in the public offering. The Company intends...

NEW YORK & ISTANBUL--(BUSINESS WIRE)--Semaglutide cuts kidney disease risk by 26% in T2D patients, confirms large real-world study by Columbia Data Analytics and partners....

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Quiver Bioscience (“Quiver”), a discovery technology and therapeutics company advancing programs for treatment of serious central nervous system (CNS) disorders and chronic pain, announced the appointment of co-founder Graham Dempsey, PhD as Chief Executive Officer. Dr. Dempsey assumes the CEO role after more than a decade of scientific and operational leadership at Quiver, most recently serving as Quiver’s Chief Scientific Officer, directing the planning and...

EL CAJON, Calif.--(BUSINESS WIRE)--PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal third quarter ended April 30, 2025. Summary of Results of Operations – Fiscal Third Quarter Net product sales were $489,000 and $440,000 for the fiscal third quarter ended April 30, 2025 and 2024, respectively. The increase of $49,000 was attributable to increased s...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--İş Private Equity, a subsidiary of Türkiye İşbank Group, has launched Enlila, a biotechnology venture, for the purpose of entering into a sponsored research agreement with the Hotamışlıgil Lab at Harvard T.H. Chan School of Public Health. Research led by Prof. Gökhan Hotamışlıgil had elucidated a fundamental mechanism underlying obesity and age-related diseases. Preclinical studies indicate that this mechanism has significant therapeutic potential, and the Hot...

DUBLIN--(BUSINESS WIRE)--The "Bioavailability and Bioequivalence Studies submitted in NDAs and INDs" training has been added to ResearchAndMarkets.com's offering. This webinar will discuss how to apply all relevant regulatory requirements for establishing the necessary BA and BE studies for INDs, NDAs and supplements to NDA. Attendees that need to perform bioavailability (BA) and bioequivalence (BE) studies for INDs, NDAs or for NDA supplements should attend this training. They will learn the r...

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins (Paris:ERF): Purchases of own shares from June 9th to June 13th 2025   Name of the Issuer Identity code of the Issuer Day of the transaction Identity code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) EUROFINS 529900JEHFM47DYY3S57 09/06/2025 FR0014000MR3 20,000 58.3921 XPAR EUROFINS 529900JEHFM47DYY3S57 10/06/2025 FR0014000MR3 20,000 58.8216 XPAR EU...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and AbbVie announced today the outcome from the Phase III VERONA study (NCT04401748) investigating Venclexta® (venetoclax) plus azacitidine for patients with previously untreated higher-risk myelodysplastic syndromes (MDS). The study did not meet the primary endpoint of overall survival at the final analysis. The safety profile of the Venclexta combination was consistent with the k...